Fundraising Fox

EvolveImmune Therapeutics Holding

Branford, US · Founded 2019 · Delaware LLC · 3 known investors

Biotech

Founders & leadership

DL
Donmienne LeungManager
IT
Ian TaylorManager
SB
Stephen BlochCEO and Manaager
AD
Alessandra Di BaccoManager
HB
Hugo BeekmanManager

Board

DY
Derek YoonManager
JM
Jasmina MarjanovicinManagerPartner at Takeda Ventures
DP
Denis PatrickManager

Investors · 3

Pfizer Venture Investmentsreported · 2 sources$5M – $20M
Solasta Venturesreported · 2 sourcesBoston
Takeda Venturesreported · 3 sourcesCambridge · $1M – $5Mvia Jasmina Marjanovic · board

Reported raises · per SEC filings

Form D private placements

$85.8M disclosed across 4 rounds · 2020–2024

▶$20MraisedNov 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Donmienne LeungDirector
  • Ian TaylorDirector
  • Derek YoonDirector
  • Stephen BlochExecutive Officer, Director
  • Jasmina MarjanovicDirector
  • Denis PatrickDirector
Offering amount
$20M
Amount sold
$20M
First sale
Oct 2024
Incorporated
Limited Liability Company, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$37.4MraisedNov 2023 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Denis PatrickDirector
  • Derek YoonDirector
  • Ian TaylorDirector
  • Stephen BlochExecutive Officer, Director
  • Alessandra Di BaccoDirector
Offering amount
$57.4M
Amount sold
$37.4M
First sale
Nov 2023
Incorporated
Limited Liability Company, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.8MraisedJan 2023 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Denis PatrickDirector
  • Derek YoonDirector
  • Ian TaylorDirector
  • Stephen BlochExecutive Officer, Director
  • Alessandra Di BaccoDirector
Offering amount
$26M
Amount sold
$10.8M
First sale
Jan 2023
Incorporated
Limited Liability Company, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17.5MraisedJan 2020 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen BlochExecutive Officer
  • Alessandra Di BaccoDirector
  • Hugo BeekmanDirector
  • Denis PatrickDirector
Offering amount
$35.1M
Amount sold
$17.5M
First sale
Jan 2020
Incorporated
Limited Liability Company, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

EvolveImmune Therapeutics Holding Company, LLC announced that it has received $37.398371 million in funding from Takeda Ventures, Inc., Pfizer Venture Investments LLC, Solasta Ventures, Inc, Bristol-Myers Squibb Company and other investors | MarketScreenermarketscreener.com · Dec 2023

Frequently asked questions

Who are EvolveImmune Therapeutics Holding's investors?
EvolveImmune Therapeutics Holding's investors include Pfizer Venture Investments, Solasta Ventures, Takeda Ventures.
How much funding has EvolveImmune Therapeutics Holding raised?
EvolveImmune Therapeutics Holding has disclosed $85.8M raised across 4 rounds.
Where is EvolveImmune Therapeutics Holding headquartered?
EvolveImmune Therapeutics Holding is headquartered in Branford, US.